Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Juncell Therapeutics Co. Ltd. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This volume of activity suggests a targeted approach to their intellectual property, likely focusing on a specific biological discovery. The concentration of efforts in the Biotechnology & Pharmaceuticals sector indicates that the company's current legal strategy is centered on this technical domain.
The prosecution is managed by 1 distinct examiner and 1 distinct art unit, ensuring a highly focused examination environment. This alignment between 1 distinct examiner and 1 distinct art unit allows for a consistent dialogue between the applicant and the USPTO, as there are no conflicting viewpoints from other examiners. The presence of 1 distinct art unit suggests that the technology is classified within a specific and well-defined technical niche.
MIANO, JOSEPH PAUL is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending action. As the examiner assigned to the company's active matter, MIANO, JOSEPH PAUL will determine the immediate success of the prosecution. Practitioners should review the examiner's history within the Biotechnology & Pharmaceuticals field to better anticipate potential rejections for the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000122 | SEED CELL MEDIUM OF TUMOR-INFILTRATING LYMPHOCYTE AND APPLICATION THEREOF | MIANO, JOSEPH PAUL | 28d overdue |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18000122 | SEED CELL MEDIUM OF TUMOR-INFILTRATING LYMPHOCYTE AND APPLICATION THEREOF | MIANO, JOSEPH PAUL | 1631 | §103Other | Non-Final OA | 28d overdue | Pending | Nov 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial